James B. Bussel, MD
Dr. James B. Bussel is the Director of the platelet disorders program; Professor of pediatrics in medicine and obstetrics/gynecology at Weill Medical College of Cornell University; and an Attending Physician at New York-Presbyterian Hospital. He is board certified in pediatric hematology-oncology and paediatrics.
Dr. Bussel’s research focuses on understanding the pathophysiology of, and improved treatments for, thrombocytopenia, particularly immune thrombocytopenia (ITP) and alloimmune thrombocytopenia, which affected fetuses. Dr. Bussel is a nationally and internationally renowned educator and recognized leader in clinical research trials in ITP and has performed seminal studies in the management of low platelet counts using intravenous immunoglobulin, rituximab, and the thrombopoietin agents. He is the primary investigator of the Cornell-Columbia TMH Clinical Trial Network and written or co-written more than 400 manuscripts, including 6 original articles in The New England Journal of Medicine and 6 in Lancet. He developed the first successful management program for fetal alloimmune thrombocytopenia, which led to him being awarded the King Faisal International Prize in Medicine for 2012.
Dr. Bussel earned an MD degree from Columbia University College for Physicians & Surgeons; completed a pediatrics residency at Cincinnati Children’s Hospital Medical Center, Ohio; and completed a joint fellowship in pediatric hematology/oncology at Memorial Sloan Kettering Cancer Center and the New York Hospital-Cornell Medical Center.
Howard A. Liebman, MA, MD, FACP
Dr. Howard A. Liebman is Professor of Medicine and Pathology at the Keck School of Medicine of USC in Los Angeles. He serves as Medical Director of the special hemostasis laboratory at USC’s Norris Comprehensive Cancer Center and is Director of the fellowship program in hematology.
Dr Liebman’s research interests include clinical management and characterization of hemostatic and thrombotic disorders, management of autoimmune blood disorders with a special interest in immune thrombocytopenia, and clinical therapy of HIV and AIDS. He has written or co-written 108 peer-reviewed publications and 33 reviews and chapters. Dr. Liebman is a member of the American Society of Clinical Oncology committee for guidelines on the prevention and management of cancer-related thrombosis, Co-Chair of the haemostasis and malignancy subcommittee of the International Society of Thrombosis and Haemostasis, and a member of the education committee of the American Society of Hematology.
Dr. Liebman earned an MD degree from USC and completed an internal medicine residency and medical oncology/hematology joint fellowships at Los Angeles County - USC Medical Center. He then completed a research fellowship at Tufts University - New England Medical Center in Boston.